Konu "Ankylosing spondylitis" için listeleme
Toplam kayıt 11, listelenen: 1-11
-
Angioedema in a patient with ankylosing spondylitis treated with etanercept
(Türkiye Klinikleri Yayınevi, 2023)Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown pathogenesis. Nonsteroidal antiinflammatory and biologic drugs are used in its treatment. A 38 year old male patient diagnosed with AS was admitted ... -
Arterial stiffness and anti-tumor necrosis factor-alpha therapy in ankylosing spondylitis: results with long-term two year-follow-up
(Turkish League Against Rheumatism, 2014)Amaç: Bu prospektif klinik çalışma ankilozan spondilit'de damar sertliği üzerine anti-tümör nekroz faktör-alfa (TNF-?) tedavisinin uzun dönemde etkinliğini değerlendirmeyi amaçlamaktadır. Hastalar ve yöntemler: Toplam 28 ... -
Association of serum interleukin-17 and Interleukin-23 levels with disease activity, function, mobility, enthesitis index in patients with ankylosing spondylitis
(Georg Thieme Verlag, 2022)Aim: More and more studies have demonstrated that the interleukin (IL)-23/IL-17 axis is highly associated with immune dysfunction and activated autoimmune inflammation. The purposes of this study were to determine the serum ... -
The development of ankylosing spondylitis in a patient with familial hemophilia
(Wiley, 2023)Hemophilia is a rare inherited disease which causes bleeding due to Factor VIII or Factor IX deficiency. It is usually X-linked recessive and typically affects males. Arthropathy occurs as a result of cartilage damage and ... -
Drug repositioning approach for the treatment of ankylosing spondylitıs
(Ankara University, 2022)Objective: In this study, it was aimed to determine an FDA-approved molecule that inhibits the IL-17 receptor, which is an important target for the prevention of inflammation in Ankylosing Spondylitis (AS), using the ... -
The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis
(Springer Heidelberg, 2017)In ankylosing spondylitis (AS) patients, cardiac and vascular involvement may manifest as atherosclerosis and coronary artery disease. Systemic inflammation, oxidative stress, increased low-density lipoprotein (LDL) ... -
Plasma leptın status and the relatıonshıp between dıfferent medıcal treatments used ın ankylosıng spondylıtıs
(Nobel Ilac, 2013)Objective: To determine plasma leptin level in ankylosing spondylitis (AS) and its correlation with disease activity measurements. To examine the effects of different treatment modalities on leptin levels. Material and ... -
Relationship between galectin-3 level and disease activity in ankylosing spondylitis patients
(Springer, 2023)Background and aimsAnkylosing spondylitis (AS) is a chronic inflammatory disease that chiefly affects the sacroiliac joints and the spine. Galectin-3, a chimera-type member of the galectin family, binds glycoconjugates ... -
The relationship between serum YKL-40 levels and arterial stiffness in patients with ankylosing spondylitis
(Publisaude-Edicoes Medicas Lda, 2017)Objective: Serum YKL-40 plays roles in inflammatory and vascular processes. Our aim was to evaluate serum YKL-40 levels in patients with ankylosing spondylitis (AS) and to investigate their potential relationship with ... -
Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis
(Springer London Ltd, 2016)Patients with ankylosing spondylitis (AS) reportedly have a higher mortality and morbidity risk. Osteoprotegerin (OPG) was recently defined as an important cardiovascular (CV) marker in the general population. We aimed to ... -
Vestibular evoked myogenic potentials in patients with ankylosing spondylitis
(Springer, 2016)Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease with unknown etiology. Although sacroiliac joint involvement is the classic sign along with the formed immune mediators, it may result in immune-mediated ...